Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Enhanced Transduction of Macaca fascicularis Hematopoietic Cells with Chimeric Lentiviral Vectors.

Sii-Felice K, Castillo Padilla J, Relouzat F, Cheuzeville J, Tantawet S, Maouche L, Le Grand R, Leboulch P, Payen E.

Hum Gene Ther. 2019 Oct;30(10):1306-1323. doi: 10.1089/hum.2018.179. Epub 2019 May 15.

PMID:
30848170
2.

Eosinophilic esophagitis: Pathophysiology, diagnosis, and management.

Vinit C, Dieme A, Courbage S, Dehaine C, Dufeu CM, Jacquemot S, Lajus M, Montigny L, Payen E, Yang DD, Dupont C.

Arch Pediatr. 2019 Apr;26(3):182-190. doi: 10.1016/j.arcped.2019.02.005. Epub 2019 Mar 1. Review.

PMID:
30827775
3.

Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.

Sii-Felice K, Giorgi M, Leboulch P, Payen E.

Exp Hematol. 2018 Aug;64:12-32. doi: 10.1016/j.exphem.2018.05.004. Epub 2018 May 26. Review.

PMID:
29807062
4.

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.

Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M.

N Engl J Med. 2018 Apr 19;378(16):1479-1493. doi: 10.1056/NEJMoa1705342.

5.

Ex Vivo Selection of Transduced Hematopoietic Stem Cells for Gene Therapy of β-Hemoglobinopathies.

Bhukhai K, de Dreuzy E, Giorgi M, Colomb C, Negre O, Denaro M, Gillet-Legrand B, Cheuzeville J, Paulard A, Trebeden-Negre H, Borwornpinyo S, Sii-Felice K, Maouche L, Down JD, Leboulch P, Payen E.

Mol Ther. 2018 Feb 7;26(2):480-495. doi: 10.1016/j.ymthe.2017.10.015. Epub 2017 Oct 24.

6.

Comparative Genome Analysis Provides Insights into Both the Lifestyle of Acidithiobacillus ferrivorans Strain CF27 and the Chimeric Nature of the Iron-Oxidizing Acidithiobacilli Genomes.

Tran TTT, Mangenot S, Magdelenat G, Payen E, Rouy Z, Belahbib H, Grail BM, Johnson DB, Bonnefoy V, Talla E.

Front Microbiol. 2017 Jun 13;8:1009. doi: 10.3389/fmicb.2017.01009. eCollection 2017.

7.

de novo assembly and population genomic survey of natural yeast isolates with the Oxford Nanopore MinION sequencer.

Istace B, Friedrich A, d'Agata L, Faye S, Payen E, Beluche O, Caradec C, Davidas S, Cruaud C, Liti G, Lemainque A, Engelen S, Wincker P, Schacherer J, Aury JM.

Gigascience. 2017 Feb 1;6(2):1-13. doi: 10.1093/gigascience/giw018.

8.

Gene Therapy in a Patient with Sickle Cell Disease.

Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet JF, Grevent D, Beuzard Y, Chrétien S, Lefebvre T, Ross RW, Negre O, Veres G, Sandler L, Soni S, de Montalembert M, Blanche S, Leboulch P, Cavazzana M.

N Engl J Med. 2017 Mar 2;376(9):848-855. doi: 10.1056/NEJMoa1609677.

9.

High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing.

Ling C, Bhukhai K, Yin Z, Tan M, Yoder MC, Leboulch P, Payen E, Srivastava A.

Sci Rep. 2016 Oct 19;6:35495. doi: 10.1038/srep35495.

10.

Current and future alternative therapies for beta-thalassemia major.

de Dreuzy E, Bhukhai K, Leboulch P, Payen E.

Biomed J. 2016 Feb;39(1):24-38. doi: 10.1016/j.bj.2015.10.001. Epub 2016 Apr 6. Review.

11.

Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.

Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S, Hongeng S, Hacein-Bey S, Cavazzana M, Leboulch P, Payen E.

Hum Gene Ther. 2016 Feb;27(2):148-65. doi: 10.1089/hum.2016.007.

12.

Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles.

Prel A, Caval V, Gayon R, Ravassard P, Duthoit C, Payen E, Maouche-Chretien L, Creneguy A, Nguyen TH, Martin N, Piver E, Sevrain R, Lamouroux L, Leboulch P, Deschaseaux F, Bouillé P, Sensébé L, Pagès JC.

Mol Ther Methods Clin Dev. 2015 Oct 21;2:15039. doi: 10.1038/mtm.2015.39. eCollection 2015.

13.

Transplantation of Macaca cynomolgus iPS-derived hematopoietic cells in NSG immunodeficient mice.

Abed S, Tubsuwan A, Chaichompoo P, Park IH, Pailleret A, Benyoucef A, Tosca L, De Dreuzy E, Paulard A, Granger-Locatelli M, Relouzat F, Prost S, Tachdjian G, Fucharoen S, Daley GQ, Payen E, Chrétien S, Leboulch P, Maouche-Chrétien L.

Haematologica. 2015 Oct;100(10):e428-31. doi: 10.3324/haematol.2015.127373. Epub 2015 Jun 18. No abstract available.

14.

Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.

Negre O, Bartholomae C, Beuzard Y, Cavazzana M, Christiansen L, Courne C, Deichmann A, Denaro M, de Dreuzy E, Finer M, Fronza R, Gillet-Legrand B, Joubert C, Kutner R, Leboulch P, Maouche L, Paulard A, Pierciey FJ, Rothe M, Ryu B, Schmidt M, von Kalle C, Payen E, Veres G.

Curr Gene Ther. 2015;15(1):64-81.

15.

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.

Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, Grapton D, Paubelle E, Payen E, Beuzard Y, Leboulch P, Ribeil JA, Arlet JB, Coté F, Courtois G, Ginzburg YZ, Daniel TO, Chopra R, Sung V, Hermine O, Moura IC.

Nat Med. 2014 Apr;20(4):398-407. doi: 10.1038/nm.3468. Epub 2014 Mar 23.

PMID:
24658077
16.

Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells derived from the same transplanted β-thalassemia patient.

Tubsuwan A, Abed S, Deichmann A, Kardel MD, Bartholomä C, Cheung A, Negre O, Kadri Z, Fucharoen S, von Kalle C, Payen E, Chrétien S, Schmidt M, Eaves CJ, Leboulch P, Maouche-Chrétien L.

Stem Cells. 2013 Sep;31(9):1785-94. doi: 10.1002/stem.1436.

17.

Synergy between XANES spectroscopy and DFT to elucidate the amorphous structure of heterogeneous catalysts: TiO2-supported molybdenum oxide catalysts.

Tougerti A, Berrier E, Mamede AS, La Fontaine C, Briois V, Joly Y, Payen E, Paul JF, Cristol S.

Angew Chem Int Ed Engl. 2013 Jun 17;52(25):6440-4. doi: 10.1002/anie.201300538. Epub 2013 May 7. No abstract available.

PMID:
23653438
18.

Arrayed lentiviral barcoding for quantification analysis of hematopoietic dynamics.

Grosselin J, Sii-Felice K, Payen E, Chretien S, Tronik-Le Roux D, Leboulch P.

Stem Cells. 2013 Oct;31(10):2162-71. doi: 10.1002/stem.1383.

19.

Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.

Payen E, Leboulch P.

Hematology Am Soc Hematol Educ Program. 2012;2012:276-83. doi: 10.1182/asheducation-2012.1.276. Review.

PMID:
23233592
20.

Enhanced cell-material interactions on medium-pressure plasma-treated polyhydroxybutyrate/polyhydroxyvalerate.

Jacobs T, Declercq H, De Geyter N, Cornelissen R, Dubruel P, Leys C, Beaurain A, Payen E, Morent R.

J Biomed Mater Res A. 2013 Jun;101(6):1778-86. doi: 10.1002/jbm.a.34459. Epub 2012 Nov 30.

PMID:
23197417
21.

Plasma surface modification of polylactic acid to promote interaction with fibroblasts.

Jacobs T, Declercq H, De Geyter N, Cornelissen R, Dubruel P, Leys C, Beaurain A, Payen E, Morent R.

J Mater Sci Mater Med. 2013 Feb;24(2):469-78. doi: 10.1007/s10856-012-4807-z.

PMID:
23124527
22.

Highly controlled synthesis of nanometric gold particles by citrate reduction using the short mixing, heating and quenching times achievable in a microfluidic device.

Ftouni J, Penhoat M, Addad A, Payen E, Rolando C, Girardon JS.

Nanoscale. 2012 Aug 7;4(15):4450-4. doi: 10.1039/c2nr11666a. Epub 2012 Jun 21.

PMID:
22722332
23.

Lentivirus vectors in β-thalassemia.

Payen E, Colomb C, Negre O, Beuzard Y, Hehir K, Leboulch P.

Methods Enzymol. 2012;507:109-24. doi: 10.1016/B978-0-12-386509-0.00006-5.

PMID:
22365771
24.

Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion.

Negre O, Fusil F, Colomb C, Roth S, Gillet-Legrand B, Henri A, Beuzard Y, Bushman F, Leboulch P, Payen E.

Blood. 2011 May 19;117(20):5321-31. doi: 10.1182/blood-2010-01-263582. Epub 2011 Mar 24.

25.

Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia.

Ronen K, Negre O, Roth S, Colomb C, Malani N, Denaro M, Brady T, Fusil F, Gillet-Legrand B, Hehir K, Beuzard Y, Leboulch P, Down JD, Payen E, Bushman FD.

Mol Ther. 2011 Jul;19(7):1273-86. doi: 10.1038/mt.2011.20. Epub 2011 Mar 8.

26.

Is normal hematopoiesis maintained solely by long-term multipotent stem cells?

Cavazzana-Calvo M, Fischer A, Bushman FD, Payen E, Hacein-Bey-Abina S, Leboulch P.

Blood. 2011 Apr 28;117(17):4420-4. doi: 10.1182/blood-2010-09-255679. Epub 2011 Feb 8. Review.

27.

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chrétien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chrétien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P.

Nature. 2010 Sep 16;467(7313):318-22. doi: 10.1038/nature09328.

28.

Death switch for gene therapy: application to erythropoietin transgene expression.

Souza DS, Spencer DM, Salles TS, Salomão MA, Payen E, Beuzard Y, Carvalho HF, Costa FF, Saad ST.

Braz J Med Biol Res. 2010 Jul;43(7):634-44. Epub 2010 May 21.

29.

Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.

Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrère F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougnères P, Von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P.

Science. 2009 Nov 6;326(5954):818-23. doi: 10.1126/science.1171242.

30.

Therapy of anemia in kidney failure, using plasmid encoding erythropoietin.

Richard-Fiardo P, Payen E, Chèvre R, Zuber J, Letrou-Bonneval E, Beuzard Y, Pitard B.

Hum Gene Ther. 2008 Apr;19(4):331-42. doi: 10.1089/hum.2006.0101.

PMID:
18341422
31.

Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment.

Fabre EE, Bigey P, Beuzard Y, Scherman D, Payen E.

Genet Vaccines Ther. 2008 Mar 11;6:10. doi: 10.1186/1479-0556-6-10.

32.

Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.

Negre O, Fusil F, Henri A, Villette JM, Leboulch P, Beuzard Y, Payen E.

Exp Hematol. 2008 Apr;36(4):412-23. doi: 10.1016/j.exphem.2007.12.004. Epub 2008 Mar 4.

PMID:
18295963
33.

Amorphous oxide as a novel efficient catalyst for direct selective oxidation of methanol to dimethoxymethane.

Royer S, Sécordel X, Brandhorst M, Dumeignil F, Cristol S, Dujardin C, Capron M, Payen E, Dubois JL.

Chem Commun (Camb). 2008 Feb 21;(7):865-7. doi: 10.1039/b714260a. Epub 2007 Dec 20.

PMID:
18253530
34.

Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.

De Franceschi L, Platt OS, Malpeli G, Janin A, Scarpa A, Leboeuf C, Beuzard Y, Payen E, Brugnara C.

FASEB J. 2008 Jun;22(6):1849-60. doi: 10.1096/fj.07-098921. Epub 2008 Feb 1.

PMID:
18245171
35.

Synthesis and structural characterization of a new nanoporous-like Keggin heteropolyanion salt: K3(H2O)4[H2SiVW11O40](H2O)8+x.

de Paiva Floro Bonfim R, de Moura LC, Pizzala H, Caldarelli S, Paul S, Eon JG, Mentré O, Capron M, Delevoye L, Payen E.

Inorg Chem. 2007 Sep 3;46(18):7371-7. Epub 2007 Aug 10.

PMID:
17691723
36.

A well-defined silica-supported dinuclear tungsten(III) amido species: synthesis, characterization and reactivity.

Gauvin RM, Coutelier O, Berrier E, Mortreux A, Delevoye L, Paul JF, Mamède AS, Payen E.

Dalton Trans. 2007 Aug 7;(29):3127-30. Epub 2007 Jun 15.

PMID:
17637987
37.

Peptide immobilization on amine-terminated boron-doped diamond surfaces.

Coffinier Y, Szunerits S, Jama C, Desmet R, Melnyk O, Marcus B, Gengembre L, Payen E, Delabouglise D, Boukherroub R.

Langmuir. 2007 Apr 10;23(8):4494-7. Epub 2007 Mar 17.

PMID:
17367174
38.

Preparation of superhydrophobic silicon oxide nanowire surfaces.

Coffinier Y, Janel S, Addad A, Blossey R, Gengembre L, Payen E, Boukherroub R.

Langmuir. 2007 Feb 13;23(4):1608-11. Epub 2007 Jan 9.

PMID:
17279635
39.

CO adsorption on CoMo and NiMo sulfide catalysts: a combined IR and DFT study.

Travert A, Dujardin C, Maugé F, Veilly E, Cristol S, Paul JF, Payen E.

J Phys Chem B. 2006 Jan 26;110(3):1261-70.

PMID:
16471673
40.

A new experimental cell for in situ and operandoX-ray absorption measurements in heterogeneous catalysis.

Girardon JS, Khodakov AY, Capron M, Cristol S, Dujardin C, Dhainaut F, Nikitenko S, Meneau F, Bras W, Payen E.

J Synchrotron Radiat. 2005 Sep;12(Pt 5):680-4. Epub 2005 Aug 16.

PMID:
16120995
41.

Preparation and characterization of 6-molybdocobaltate and 6-molybdoaluminate cobalt salts. Evidence of a new heteropolymolybdate structure.

Martin C, Lamonier C, Fournier M, Mentré O, Harlé V, Guillaume D, Payen E.

Inorg Chem. 2004 Jul 26;43(15):4636-44.

PMID:
15257593
42.

Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.

Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, Eaves CJ, Cavilla B, Wadsworth LD, Beuzard Y, Bouhassira EE, Russell R, London IM, Nagel RL, Leboulch P, Humphries RK.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14380-5. Epub 2002 Oct 21.

43.

Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts.

Sommer B, Rinsch C, Payen E, Dalle B, Schneider B, Déglon N, Henri A, Beuzard Y, Aebischer P.

Mol Ther. 2002 Aug;6(2):155-61.

44.

Hydrogen activation on Mo-based sulfide catalysts, a periodic DFT study.

Travert A, Nakamura H, van Santen RA, Cristol S, Paul JF, Payen E.

J Am Chem Soc. 2002 Jun 19;124(24):7084-95.

PMID:
12059233
45.

Correction of sickle cell disease in transgenic mouse models by gene therapy.

Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, Acharya SA, Ellis J, London IM, Eaves CJ, Humphries RK, Beuzard Y, Nagel RL, Leboulch P.

Science. 2001 Dec 14;294(5550):2368-71.

46.

Oxygen tension and a pharmacological switch in the regulation of transgene expression for gene therapy.

Payen E, Bettan M, Henri A, Tomkiewitcz E, Houque A, Kuzniak I, Zuber J, Scherman D, Beuzard Y.

J Gene Med. 2001 Sep-Oct;3(5):498-504.

PMID:
11601763
47.

Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo.

Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E.

Blood. 2001 Jun 15;97(12):3776-82.

PMID:
11389016
48.

Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA.

Payen E, Bettan M, Rouyer-Fessard P, Beuzard Y, Scherman D.

Exp Hematol. 2001 Mar;29(3):295-300.

PMID:
11274756
49.

Modulation of transduced erythropoietin expression by iron.

Dalle B, Payen E, Beuzard Y.

Exp Hematol. 2000 Jul;28(7):760-4.

PMID:
10907637
50.

Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts.

Dalle B, Payen E, Regulier E, Deglon N, Rouyer-Fessard P, Beuzard Y, Aebischer P.

Gene Ther. 1999 Feb;6(2):157-61.

Supplemental Content

Support Center